FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ November 22, 2018 Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Can AI Help Predict Which Cancer Patients Should Be Treated with... February 26, 2025 ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... January 31, 2022 Load more HOT NEWS Courageous children receive Star Awards in virtual celebration Anal Cancer Incidence and Deaths Are Rising in the United States Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory... Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable...
